A conclusive study was conducted for preparation and evaluation of combinedinactivated entero-4 vaccine containing bovine rotavirus (BRV), bovine coronavirus(BCV), E. coli K99 and toxoid of C. perfringens type "C". Laboratory and field evaluations were conducted on laboratory animals, calves and late pregnant cows with monitoring the active and passive antibodies in vaccinated cows and their offspring respectively. Laboratory evaluation proved purity, safety and high efficacy of the vaccine without interference between different vaccine ingredients. Field evaluation gave satisfactory results when pregnant cows vaccinated at late stage of pregnancy with high neutralizing antibody titers against BRV, BCV and C. perfringens as well as high E. coli agglutinating titers. Maternal immunity passively protected offspring during the critical period of age and remained protected till the end of sampling time (30th day post parturition).

To evaluate site-to-site variation within fecal pats from cattle with regard to detection of Escherichia coli O157 and determine the effect on the accuracy of prevalence estimates of assay of multiple samples collected from the same fecal pat. 120 freshly voided fecal pats collected from 2 beef feedlots. Procedures-5 samples were systematically collected from each fecal pat and analyzed for E coli O157 via selective preenrichment techniques, immunomagnetic separation, and biochemical tests. Presumptive isolates were definitively identified via agglutination assays and polymerase chain reaction techniques. Best estimators of prevalence were calculated from the distribution of E coli O157-positive samples per pat. Of the 120 fecal pats, 96, 13, 4, 2, 3, and 2 fecal pats had 0, 1, 2, 3, 4, and 5 E coli O157-positive samples, respectively. The greatest estimate of E coli O157 prevalence (20%) was achieved when all 5 samples were assessed; this estimate represented a 2.4- fold increase in prevalence, compared with that provided via analysis of 1 sample/pat (8.2%). Compared with assessment of 5 sites/pat, the relative sensitivity of detecting an E coli O157-positive fecal pat via analysis of 1 site/pat was 40.1%. Results suggest that estimates of E coli O157 prevalence derived from sampling of 1 location/pat are likely underestimates of the true prevalence of this pathogen in fecal pats (and by extension, cattle). Additional research is warranted to confirm these results in situations of high and low prevalence and across different feedlots.

An experimental chlorate product (ECP) developed by the United States Department of Agriculture has been shown to have bactericidal effects against enteropathogens such as Escherichia coli. In studies with broilers and pigs, the bactericidal activity of ECP was enhanced by prior adaptation of gastrointestinal microflora to nitrate. The objective of this study was to examine the effects of nitrate adaptation on the bactericidal activity of ECP against E. coli in Holstein steers. Results indicate that ECP was effective at reducing E. coli. However, ECP did not reduce E. coli in a dose-dependent manner, indicating that the highest ECP dose provided in this study exceeded that needed to be efficacious. Adapting gastrointestinal microflora with nitrate prior to feeding ECP did not improve efficacy of ECP against E. coli. Rapid reduction of nitrate in the rumen is implicated as a possible explanation for why adaptation to nitrate did not enhance the bactericidal effects of ECP in cattle.